Year in Review
Year ended March 2022
Key Figures
- Net Sales
- ¥1,013.0billion
- 15.0%
- Operating Income
- ¥92.9billion
- 12.4%
- Operating Income Ratio
- 9.2%
- 0.3percentage points
- ROE
- 13.5%
- 2.4percentage points
- Capital Expenditures
- ¥93.1billion
- R&D Expenses
- ¥33.4billion
Breakdown by Segment
- Food
- Pharmaceuticals
Net Sales
Operating Income
Business Performance Analysis
Food
- Net Sales
- ¥826.0billion
- 17.4%
- Operating Income
- ¥75.9billion
- 13.1%
- Income Analysis(Billions of yen)
-
Pharmaceuticals
- Net Sales
- ¥187.9billion
- 2.9%
- Operating Income
- ¥18.6billion
- 2.3%
- Income Analysis(Billions of yen)
-
Capital Expenditures
- Food
- Pharmaceuticals
Food
¥75.9billion
Pharmaceuticals
¥17.0billion
Cash Dividends per Share / Dividend Payout Ratio
- Cash Dividends per Share
Dividend Payout Ratio
Future Prospects
This is our Medium-term Business Plan,
FYE 3/2022 through FYE 3/2024.
- Net sales
- Operating income
- Operating income ratio
- ROE
- FYE 3/2021
Results - ¥1,007.1 billion
- ¥106.0 billion
- 10.5%
- 11.1%
- FYE 3/2022
Results - ¥1,013.0 billion
- ¥92.9 billion
- 9.2%
- 13.5%
- FYE 3/2024
Targets * - ¥1,080.0 billion
- ¥120.0 billion
- 11.1%
- 11.0%
* as of May 18, 2021